Aimmune Therapeutics, Inc. Form SC 13G/A February 13, 2018

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Schedule 13G (Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)

(Amendment No. 3)*

Aimmune Therapeutics, Inc. (Name of Issuer)

Common Stock (Title of Class of Securities)

00900T107 (CUSIP Number)

December 31, 2017 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

	Rule 13d-1(b)
x	Rule 13d-1(c)
	Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on following pages)

Page 1 of 11

Exhibit Index on Page 10

CUSIP # 00900T107 Page 2 of 11

CHECK THE A	ORTING PERSONS Foresite Capital Fund II, PPROPRIATE BOX IF A MEMBER OF A GROUP	,	FCF II"			
2		(a)		(b)	Х	
3 SEC USE ONLY CITIZENSHIP O Delaware	R PLACE OF ORGANIZATION					
	SOLE VOTING POWER 3,100,146 shares, except that Foresite Capital Mar of FCF II, may be deemed to have sole power to v 5("Tananbaum"), the managing member of FCM II shares.	vote thes	e share	s, and Ja	ames Tai	nanbaum
NUMBER OF						
SHARES						
BENEFICIALLY	6 SHARED VOTING POWER					
OWNED BY	See response to row 5.					
EACH	SOLE DISPOSITIVE POWER					
REPORTING						
PERSON WITH	 73,100,146 shares, except that FCM II, the general power to dispose of these shares, and Tananbaum deemed to have sole power to dispose of these sha 8 SHARED DISPOSITIVE POWER See response to row 7. 	, the mai		•		
	AMOUNT BENEFICIALLY OWNED BY EACH F F THE AGGREGATE AMOUNT IN ROW (9) EXC	-				3,100,146
PERCENT OF	CLASS REPRESENTED BY AMOUNT IN ROW 9)				
11						6.1%
12TYPE OF REP	ORTING PERSON					PN

12TYPE OF REPORTING PERSON

PN

CUSIP # 00900T107 Page 3 of 11

	ORTING PERSONS Foresite Capital Manag PROPRIATE BOX IF A MEMBER OF A GROU		, LLC ("FCM I	I")	
2		(a)		(b)	Х	
3 SEC USE ONLY 4 CITIZENSHIP O 4 Delaware NUMBER OF SHARES	PR PLACE OF ORGANIZATION SOLE VOTING POWER 3,100,146 shares, all of which are directly owned FCM II, the general partner of FCF II, may be de 5 and James Tananbaum ("Tananbaum"), the mana sole power to vote these shares.	eemed to	have so	ole powe	er to vote	e these shares,
BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	 ⁶SHARED VOTING POWER ⁶See response to row 5. SOLE DISPOSITIVE POWER ⁷3,100,146 shares, all of which are directly owned ⁷II, may be deemed to have sole power to dispose ⁸member of FCM II, may be deemed to have sole ⁸SHARED DISPOSITIVE POWER ⁸See response to row 7. 	of these	shares,	and Ta	nanbaum	, the managing
10CHECK BOX I	AMOUNT BENEFICIALLY OWNED BY EACH F THE AGGREGATE AMOUNT IN ROW (9) EX CLASS REPRESENTED BY AMOUNT IN ROW	CLUDE				3,100,146 6.1%
12TYPE OF REPO	ORTING PERSON					00

CUSIP # 00900T107 Page 4 of 11

	ORTING PERSONS Foresite Capital Fu PROPRIATE BOX IF A MEMBER OF A GR		FIII")	
2		(a)	(b)	Х
Delaware NUMBER OF	R PLACE OF ORGANIZATION SOLE VOTING POWER 764,824 shares, except that Foresite Capital of FCF III, may be deemed to have sole pow 5("Tananbaum"), the managing member of For these shares.	ver to vote these sl	nares, and J	ames Tananbaum
SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	 ⁶SHARED VOTING POWER ⁶See response to row 5. SOLE DISPOSITIVE POWER ⁷764,824 shares, except that FCM III, the ger ⁷power to dispose of these shares, and Tanan ⁸deemed to have sole power to dispose of the ⁸SHARED DISPOSITIVE POWER ⁸See response to row 7. 	baum, the managi	CF III, may ng member	be deemed to have sole of FCM III, may be
10CHECK BOX I PERCENT OF O	AMOUNT BENEFICIALLY OWNED BY EA F THE AGGREGATE AMOUNT IN ROW (9 CLASS REPRESENTED BY AMOUNT IN R) EXCLUDES CE		
11				1.5%
12 TYPE OF REPORTING PERSON			PN	

CUSIP # 00900T107 Page 5 of 11

	ORTING PERSONS Foresite Capital Manage PROPRIATE BOX IF A MEMBER OF A GROUP		, LLC ("FCM I	II")	
2		(a)		(b)	Х	
3 SEC USE ONLY 4 CITIZENSHIP O Delaware NUMBER OF	R PLACE OF ORGANIZATION SOLE VOTING POWER 764,824 shares, all of which are directly owned by FCM III, the general partner of FCF III, may be d 5 and James Tananbaum ("Tananbaum"), the mana sole power to vote these shares.	eemed to	b have s	sole pow	ver to vot	te these shares,
SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	 ⁶SHARED VOTING POWER ⁶See response to row 5. SOLE DISPOSITIVE POWER ⁷764,824 shares, all of which are directly owned by III, may be deemed to have sole power to dispose member of FCM III, may be deemed to have sole ⁸SHARED DISPOSITIVE POWER ⁸See response to row 7. 	of these	shares,	, and Ta	nanbaum	, the managing
10CHECK BOX I PERCENT OF O	AMOUNT BENEFICIALLY OWNED BY EACH I F THE AGGREGATE AMOUNT IN ROW (9) EXC CLASS REPRESENTED BY AMOUNT IN ROW 9	CLUDES				764,824
11						1.5%
12TYPE OF REPO	DRTING PERSON					00

CUSIP # 00900T107 Page 6 of 11

1 NAME OF REPORTING PERSONSJames Tananbaum ("Tananbaum")CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP				
2	(a) " (b) x			
3 SEC USE ONL 4 CITIZENSHIP (4 United States	OR PLACE OF ORGANIZATION			
	SOLE VOTING POWER 3,864,970 shares, of which 3,100,146 shares are directly owned by Foresite Capita ("FCF II"), and 764,824 shares are directly owned by Foresite Capital Fund III, L Tananbaum is the managing member of each of Foresite Capital Management II, I	.P. ("FCF III"). LLC ("FCM II"),		
	5 which is the general partner of FCF II, and Foresite Capital Management III, LLC which is the general partner of FCF III. Tananbaum may be deemed to have sole			
NUMBER OF SHARES BENEFICIALLY	these shares.			
OWNED BY	, SHARED VOTING POWER			
EACH	⁶ See response to row 5.			
REPORTING	SOLE DISPOSITIVE POWER			
PERSON	3,864,970 shares, of which 3,100,146 shares are directly owned by FCF II, and 76			
WITH	7 are directly owned by FCF III. Tananbaum is the managing member of each FCM general partner of FCF II, and FCM III, which is the general partner of FCF III. T be deemed to have sole power to dispose of these shares. 8 SHARED DISPOSITIVE POWER			
	See response to row 7.	2 964 070		
10CHECK BOX	E AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES CLASS REPRESENTED BY AMOUNT IN ROW 9	3,864,970 		
11		7.6%		
12TYPE OF REP	PORTING PERSON	IN		

12TYPE OF REPORTING PERSON

IN

CUSIP # 00900T107 Page 7 of 11

ITEM 1(A).

NAME OF ISSUER

Aimmune Therapeutics, Inc. (the "Issuer")

ITEM 1(B).

ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES

8000 Marina Blvd., Suite 300

Brisbane, CA 94005

ITEM 2(A).

NAME OF PERSONS FILING

This Schedule is filed by Foresite Capital Fund II, L.P., a Delaware limited partnership, Foresite Capital Management II, LLC, a Delaware limited liability company, Foresite Capital Fund III, L.P., a Delaware limited partnership, Foresite Capital Management III, LLC, a Delaware limited liability company and James Tananbaum. The foregoing entities and individuals are collectively referred to as the "Reporting Persons."

ITEM 2(B).

ADDRESS OF PRINCIPAL OFFICE

The address for each of the Reporting Persons is:

c/o Foresite Capital Management

600 Montgomery Street, Suite 4500 San Francisco, CA 94111

ITEM 2(C).

CITIZENSHIP

See Row 4 of cover page for each Reporting Person.

9

Edgar Filing: Aimmune Therapeutics, Inc. - Form SC 13G/A

ITEM 2(D). <u>TITLE OF CLASS OF SECURITIES</u>

Common Stock

ITEM 2(D)

CUSIP NUMBER

00900T107

ITEM 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

Not applicable.

ITEM 4.

<u>OWNERSHIP</u>

The following information with respect to the ownership of the common stock of the Issuer by the persons filing this Statement is provided as of December 31, 2017:

(a)

Amount beneficially owned:

See Row 9 of cover page for each Reporting Person.

(b)

See Row 11 of cover page for each Reporting Person.

4.

Percent of Class:

CUSIP # 00900T107 Page 8 of 11

(c)	Number of shares as to which such person has:
(i)	Sole power to vote or to direct the vote:
See Row 5 of cover page for each Report	ing Person.
(ii)	Shared power to vote or to direct the vote:
See Row 6 of cover page for each Report	ing Person.
(iii)	Sole power to dispose or to direct the disposition of:
See Row 7 of cover page for each Report	ing Person.
(iv)	Shared power to dispose or to direct the disposition of:
See Row 8 of cover page for each Report	ing Person.
ITEM 5. <u>O</u>	WNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
Not applicable.	

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

Under certain circumstances set forth in the limited partnership agreements of FCF II and FCF III and the limited liability company agreements of FCM II and FCM III the partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from the sale of, shares of the

Edgar Filing: Aimmune Therapeutics, Inc. - Form SC 13G/A

Issuer directly or indirectly owned by each such entity of which they are a partner or member.

ITEMIDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE7.SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

Not applicable.

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

Not applicable

ITEM 9.

NOTICE OF DISSOLUTION OF GROUP.

Not applicable

ITEM 10.

CERTIFICATION.

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

CUSIP # 00900T107 Page 9 of 11

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 13, 2018

FORESITE CAPITAL FUND II, L.P.

By: FORESITE CAPITAL MANAGEMENT II, LLC Its: General Partner

By: /s/ James Tananbaum Name: James Tananbaum Title: Managing Member

FORESITE CAPITAL MANAGEMENT II, LLC

By: /s/ James Tananbaum Name: James Tananbaum Title: Managing Member

FORESITE CAPITAL FUND III, L.P.

By: FORESITE CAPITAL MANAGEMENT III, LLC Its: General Partner

By: /s/ James Tananbaum Name: James Tananbaum Title: Managing Member

FORESITE CAPITAL MANAGEMENT III, LLC

By: /s/ James Tananbaum Name: James Tananbaum Title: Managing Member

JAMES TANANBAUM

By: /s/ James Tananbaum Name: James Tananbaum CUSIP # 00900T107 Page 10 of 11

EXHIBIT INDEX

Found on Sequentially Numbered Page

Exhibit

Exhibit A: Agreement of Joint Filing 11

CUSIP # 00900T107 Page 11 of 11

exhibit A

Agreement of Joint Filing

The Reporting Persons hereby agree that a single Schedule 13G (or any amendment thereto) relating to the common stock of the Issuer shall be filed on behalf of each of the Reporting Persons. Note that a copy of the applicable Agreement of Joint Filing is already on file with the appropriate agencies.